{
  "programA_recommendation": "do-not-pursue",
  "programB_recommendation": "pursue-with-conditions",
  "lead_verdicts": [
    {
      "target": "GATA3",
      "verdict": "drop",
      "one_line": "Textbook Th2 TF but undruggable, broadly required; no edge over approved biologics."
    },
    {
      "target": "IL2RB",
      "verdict": "drop",
      "one_line": "Shared IL-2/IL-15 machinery; risks depleting Tregs and NK function, no advantage."
    },
    {
      "target": "IL4R",
      "verdict": "drop",
      "one_line": "Dupilumab's own target; useful only as screen positive control."
    },
    {
      "target": "BHLHE40",
      "verdict": "advance-with-conditions",
      "one_line": "Non-canonical, differentiated hit; needs confirmed Th2-selectivity in patient-derived cells."
    },
    {
      "target": "SMAD4",
      "verdict": "drop",
      "one_line": "Central TGF-beta hub and tumor suppressor; unacceptable safety profile for chronic use."
    },
    {
      "target": "STK11",
      "verdict": "advance-with-conditions",
      "one_line": "Strong anergy/Treg biology but tumor suppressor; only viable as transient adjunct dosing."
    },
    {
      "target": "SIK3",
      "verdict": "advance-with-conditions",
      "one_line": "Most tractable, dual-program hit; needs isoform-selective chemistry to avoid metabolic liability."
    },
    {
      "target": "PRKAR1A",
      "verdict": "drop",
      "one_line": "Ubiquitous PKA node linked to Carney complex; informative pathway signal only, not a target."
    }
  ],
  "recommended_modality": "Transient CRISPRi/tool-compound inhibition of STK11/SIK3 as combination adjunct alongside tolerogenic pMHC-II construct; SIK3 isoform-selective inhibitor/degrader design prioritized for chemistry stream",
  "combination_concept_coherent": true,
  "top_derisking_experiment": "In antigen-experienced/EoE patient-derived CD4+ T cells, transiently knock down or inhibit STK11/SIK3 then co-culture with tolerogenic pMHC-II construct vs. construct-alone and knockdown-alone controls, reading out TR1/iTreg conversion, suppressive function, and durability under antigen rechallenge.",
  "kill_criteria": [
    "Knockdown/inhibition fails to reproduce Th2 dampening or amenability gain in EoE patient PBMC or esophageal-biopsy T cells under allergen recall stimulation",
    "Counter-screens show comparable perturbation effects in Th1/Th17/Treg populations (selectivity ratio <2x vs Th2), indicating generic immunosuppression rather than selective reprogramming",
    "Converted cells revert to effector phenotype/cytokine output upon antigen rechallenge after extended rest, or marker induction does not correlate with actual suppression assay"
  ],
  "next_steps": [
    "Cross-validate BHLHE40, STK11, SIK3, PRKAR1A expression/regulation against public EoE patient transcriptomic datasets",
    "Compile Peutz-Jeghers, Carney complex, and SIK-inhibitor safety literature into a formal target-safety dossier",
    "Design and resource the STK11/SIK3 + pMHC combination de-risking assay, contingent on epitope/HLA-II restriction from the antigen pipeline",
    "Task protein-design/binder stream with SIK3 isoform-selective inhibitor or degrader design",
    "Flag TCR-specificity/clonotype identification as prioritization input before selecting clones for the combination experiment"
  ]
}